About Us

Leadership

President and Chief Executive Officer
Chief Medical Officer
Chief Scientific Officer
Chief Financial Officer
Chief Legal Officer
Chief People Officer
Senior Vice President, Communications and IR
Senior Vice President, Strategic Alliances and Program Management
Senior Vice President, Chemistry
Senior Vice President, Biological Sciences

Senior Vice President, Technical Operations, Quality and Facilities

Board of Directors

Marc Cohen

Co-Founder, Executive Chairman

Andrew Hirsch

President, Chief Executive Officer, Director

Alain Cohen

Director

Bruce Downey

Director

Glenn Dubin

Director

Scientific Advisory Board

Ken Anderson, M.D.

  • Kraft Family Professor of Medicine, Harvard Medical School
  • Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute

Scott Armstrong, M.D., Ph.D.

  • Chairman of the Department of Pediatric Oncology, Dana-Farber Cancer Institute
  • Associate Chief, Department of Hematology/Oncology, Boston Children’s Hospital
  • David G. Nathan Professor of Pediatrics, Harvard Medical School

Ryan B. Corcoran, M.D., Ph.D.

  • Director of the Gastrointestinal Cancer Center Program
  • Scientific Director of the Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center

Nathanael Gray, Ph.D.

  • Faculty Lead, Medicinal Chemistry Professor, Chemical and Systems Biology, Stanford University
  • Stanford Cancer Institute Director of Cancer Drug Discovery

Christopher Kirk, Ph.D.

  • President and Chief Scientific Officer, Kezar Life Sciences (NASDAQ : KZR)

Ross Levine, M.D.

  • Attending Physician on the Leukemia Service, Department of Medicine, the Laurence Joseph Dineen Chair in Leukemia Research
  • Professor of Medicine, Weill Cornell Medical College
  • Director of the MSK Center for Hematologic Malignancies

Clinical Advisory Board

Chris Bowden, M.D.

  • Strategic Advisor and Former Chief Medical Officer, Agios Pharmaceuticals (NASDAQ: AGIO)

Beni Wolf, M.D., Ph.D.

  • Chief Medical Officer, Relay Therapeutics (NASDAQ: RLAY)

Randi Isaacs, M.D.

  • Chief Medical Officer, Werewolf Therapeutics (NASDAQ: HOWL)

Hagop Youssoufian, M.D.

  • Former faculty member at Harvard Medical School and Baylor College of Medicine
  • Former CMO of ImClone-Lilly and other biotechnology companies
  • Member, American Society of Clinical Investigation

leadership-Marc-A-Cohen

Marc Cohen

CO-FOUNDER, EXECUTIVE CHAIRMAN

Marc Cohen is a co-founder and has served as a member of our Board of Directors and as Executive Chairman since our inception in October 2015. He is a co-founder and currently serves as Chief Executive Officer and Executive Chairman for NextRNA Therapeutics, a biotechnology company focused on developing the next generation of RNA-directed therapeutics. Since December 2011, Marc has served as the Chairman and co-Chief Executive Officer of Bublup, Inc., an online knowledge-sharing and organization platform, and has served as co-Chief Executive Officer of Cobro Ventures, Inc., an investment management company for technology and biotechnology companies, since October 2013. Marc is also Chairman of Frequency Therapeutics, Inc., a regenerative medicine biotechnology company, and Executive Chairman of Mana Therapeutics, Inc., a cellular therapies biotechnology company focused on educating immune cells to target cancer, positions in which he has served since September 2016 and January 2018, respectively. He has also served as Executive Chairman of Regenacy Pharmaceuticals, Inc., a biotechnology company, focused on diabetic and other peripheral neuropathies, since January 2016, Executive Chairman of OncoPep, Inc., a cancer vaccine biotechnology company, since January 2010, and Executive Chairman of Raqia Therapeutics, Inc., a CAR-T cell therapies company for cancer and other diseases, since July 2020. Mr. Cohen is also the co-founder of the Dana-Farber Innovations Research Fund, a venture philanthropy fund focused on early stage research. Mr. Cohen was co-founder and served as Chief Executive Officer and Chairman of OPNET Technologies, Inc., a software company that provided performance management tools for computer networks and applications, from 1986 through its acquisition in 2012. Mr. Cohen holds an M.S. in Electrical Engineering from Stanford University and an A.B. in Engineering Sciences from Harvard University.

leadership-Andrew-Hirsch

Andrew Hirsch

PRESIDENT, DIRECTOR

Andrew Hirsch joined C4 Therapeutics in September 2020 and serves as our President, Chief Executive Officer, and a member of our Board of Directors. Previously, Andrew was Chief Financial Officer and Head of Corporate Development at Agios Pharmaceuticals, Inc. Andrew has more than 20 years of experience in a range of strategic and operating roles in the biotechnology sector, previously serving as President and Chief Executive Officer of BIND Therapeutics, Inc. Prior to being named President and Chief Executive Officer, Andrew held several other leadership positions at BIND, including Chief Operating Officer and Chief Financial Officer. Before joining BIND, Andrew was Chief Financial Officer at Avila Therapeutics, Inc. from June 2011 until its acquisition by Celgene Corporation. From 2002 to 2011, Andrew held roles of increasing responsibility at Biogen Inc., including Vice President of Corporate Strategy and M&A and Program Executive for the Tecfidera development team. Since May 2017, Andrew has served on the Board of Directors of Editas Medicine, Inc. Andrew holds an M.B.A. from the Tuck School at Dartmouth College and a B.A. in Economics from the University of Pennsylvania.

bod-Ken-Anderson

Ken Anderson, M.D.

DIRECTOR

Ken Anderson, M.D. is a co-founder and has served as a member of our Board since December 2015. Dr. Anderson has also served as the Kraft Family Professor of Medicine at Harvard Medical School since 2002, as well as Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute since 2000 and 2007, respectively. Dr. Anderson is a member of the Institute of Medicine of the National Academy of Sciences and served as President of the International Myeloma Society from 2011 until 2015. Dr. Anderson serves on the boards of directors of Mana Therapeutics, Inc., a biotechnology company developing off-the-shelf cellular therapies for cancer patients, since January 2018, OncoPep, Inc. a biotechnology company developing targeted immunotherapeutics, since January 2010, NextRNA, a biotechnology company focused on developing the next generation of RNA-directed therapeutics, since February 2021, Raqia Therapeutics, Inc., a CAR-T cell therapies company for cancer and other diseases, since September 2020, and Starton Therapeutics, Inc., a biotechnology company focused on blood cancer treatments, since September 2020. Dr. Anderson holds an M.D. from Johns Hopkins Medical School, where he also trained in internal medicine, and completed hematology, medical oncology and tumor immunology training at Dana-Farber Cancer Institute.

bod-Alain-Cohen

Alain Cohen

DIRECTOR

Alain J. Cohen has served as a member of our Board of Directors since 2015. Since 2013, he has been the Co-Chief Executive Officer of Cobro Ventures, an investment management company for technology and biotechnology companies. Since December 2011, Alain has also been co-Chief Executive Officer of Bublup, Inc., an online knowledge-sharing and organization platform. Alain serves on the board of directors of Mana Therapeutics, Inc., a cellular therapies biotechnology company focused on educating immune cells to target cancer, as well as NextRNA, Inc., a biotechnology company focused on developing the next generation of RNA-directed therapeutics. In 1986, he co-founded and served as President and Chief Technology Officer of OPNET Technologies, Inc., a software company that provided performance management tools for computer networks and applications, through its acquisition in 2012. Alain holds a B.S. in Electrical Engineering from the Massachusetts Institute of Technology.

bod-Bruce-Downey

Bruce Downey

DIRECTOR

Bruce Downey has served as a member of our Board of Directors since December 2015. Previously, Bruce was Chairman and Chief Executive Officer of Barr Pharmaceuticals, Inc. (until its acquisition by Teva in 2008), a global generic pharmaceutical manufacturer. He has served on a part-time basis as a Partner of NewSpring Health Capital II, L.P., a venture capital firm, since April 2009. Prior to Barr Pharmaceuticals, Bruce was a practicing attorney for 20 years, working in both the private sector and for the federal government, including the U.S. Department of Justice and the U.S. Department of Energy. In addition, he serves on the boards of directors of OncoPep, Inc., a biotechnology company, and Cardinal Health, Inc., a healthcare services company since April 2011 and July 2009 respectively. Bruce previously served on the board of directors of Melinta Therapeutics, Inc., a biopharmaceutical firm, and Momenta Pharmaceuticals, a biotechnology company acquired by Johnson & Johnson. He holds a B.S. in Economics from Miami University and a J.D. from Ohio State University.

bod-Glenn-Dubin-update.jpg

Glenn Dubin

Director

Glenn Dubin has served as a member of our Board of Directors since March 2021. Glenn is the Principal of Dubin & Co., a private investment company based in New York. Since 2012, Glenn has been a member of the Board of Directors and lead shareholder of Castleton Commodities International LLC, a global merchant energy company active in the physical and financial commodity markets and infrastructure investing. Glenn co-founded Highbridge Capital Management LLC, an alternative asset management company that was acquired by JP Morgan Asset Management. Additionally, Glenn is active in a variety of philanthropic endeavors, including roles as founder and former Board chair of the Robin Hood Foundation, an organization that applies investment principles to charitable giving, the Mount Sinai Medical Center, where he and his wife, Dr. Eva Andersson-Dubin, established the Dubin Breast Center, a leading institution for breast cancer research and clinical care, and the Museum of Modern Art, where he is a member of the Board of Trustees.
bod-Elena-Prokupets

Elena Prokupets

DIRECTOR

Elena Prokupets, Ph.D. has served as a member of our Board of Directors since December 2015. Elena co-founded Lenel Systems International, a security software company, in 1991 and served as its President, CEO and Chairwoman of the Board until its sale to United Technology Corporation. She also previously co-founded and led Edicon Systems (a division of Eastman Kodak Company). Dr. Prokupets was on the board of directors of Acetylon Pharmaceuticals, Inc., a pharmaceutical company, from August 2009 until its sale to Celgene Corporation, a subsidiary of Bristol-Myers Squibb, in December 2016, and currently serves on the boards of directors of Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, NextRNA, a biotechnology company focused on an RNA target and drug discovery platform technology, and OncoPep, Inc., a biotechnology company that specializes in the development of targeted immuno-therapeutics for the treatment of cancer. She is also a Life Trustee of the University of Rochester. Elena holds an M.S. in Electrical Engineering and a Ph.D. in Computer Science from Saint Petersburg Electrotechnical University, Russia.
bod-Malcolm-Salter

Malcolm Salter

DIRECTOR

Malcolm Salter has served as a member of our Board of Directors since December 2015. Malcolm is the James J. Hill Professor, Emeritus, at the Harvard Business School. Since joining the Harvard Business School faculty in 1967, his teaching and research has focused on issues of corporate strategy and governance. He currently serves on the boards of directors of NextRNA, Inc., a biotechnology company focused on developing the next generation of RNA-directed therapeutics, since February 2021, and Raqia Therapeutics, Inc., a CAR-T cell therapies company for cancer and other diseases, since September 2020. From 1986 to 2006, he served as president of Mars & Co., a global strategy-consulting firm. He is a Trustee of the Dana-Farber Cancer Institute. Mr. Salter holds an A.B., M.B.A., and a D.B.A. from Harvard University.

sab-Nathanael-Gray

Nathanael Gray, Ph.D.

Nathanael Gray, Ph.D. is a co-founder of C4 Therapeutics and a Professor of Chemical and Systems, Biology at Stanford University and the Stanford Cancer Institute Director of Cancer Drug Discovery. Previously, Dr. Gray was a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and an Investigator at the Dana-Farber Cancer Institute. Prior to that, he was Director of Biological Chemistry at the Genomics Institute of the Novartis Research Foundation. Nathanael’s research focuses on the discovery of small molecules that impact biological pathways important in cancer. These efforts have produced numerous first-in-class kinase inhibitors that have become widely used to understand complex biology and have also inspired drug discovery programs. Nathanael’s research has been recognized by many awards including the Meyenburg Cancer Research Award, the American Chemical Society Award for Outstanding Research in Biological Chemistry, and the AACR Award for Team Science. Dr. Gray received his Ph.D. from the University of California at Berkeley. Nathanael is a founder of Syros Pharmaceuticals.
sab-Scott-Armstrong

Scott Armstrong, M.D., Ph.D.

Dr. Scott A. Armstrong is Chairman of the Department of Pediatric Oncology at Dana-Farber Cancer Institute, Associate Chief, Department of Hematology/Oncology, Boston Children’s Hospital, and the David G. Nathan Professor of Pediatrics at Harvard Medical School. Dr. Armstrong received his M.D. and Ph.D. from the University of Texas Southwestern Medical School in Dallas, Texas. He performed his residency and fellowship in pediatric hematology/oncology at Children’s Hospital Boston, the Dana Farber Cancer Institute, and Harvard Medical School. The major focus of his career has been on delineating the biology of leukemia and the development of new therapeutic approaches for cancer. His group studies how chromatin-associated complexes control cancer-causing gene expression and has used this understanding to develop small molecule approaches that he continues to pursue. This work has led to the development of clinical trials that are being assessed in adults and children with cancer. His work has been recognized by a number of awards including the Paul Marks Prize for Cancer Research from Memorial Sloan Kettering Cancer Center, the E. Mead Johnson Award for Outstanding Research in Pediatrics and the Dameshek Prize from the American Society of Hematology. He is an elected member of the National Academy of Medicine (NAM), American Society of Clinical Investigation (ASCI), the Association of American Physicians (AAP), and is a fellow of the Association for the Advancement of Science.

sab-Ross-Levine

Ross Levine, M.D.

Ross Levine, M.D., is a Member of the Human Oncology and Pathogenics Program and an Attending Physician on the Leukemia Service, Department of Medicine, the Laurence Joseph Dineen Chair in Leukemia Research, a Professor of Medicine at Weill Cornell Medical College, and is the Director of the MSK Center for Hematologic Malignancies. Dr. Levine was born and raised in the New York area, and then received his AB from Harvard College and a M.D. from Johns Hopkins. Dr. Levine served as an Resident in Internal Medicine at the MGH and subsequently as a Hematology-Oncology Fellow at DFCI. His laboratory has identified MPN predisposition alleles and characterized somatic genetic alterations in MPN patients, which has improved our understanding of the genetic basis of MPNs. In addition his lab has performed preclinical studies of JAK kinase inhibitors and HSP90 inhibitors. His lab also investigates the role of somatic mutations in epigenetic modifiers in AML and mechanisms of sensitivity and resistance to epigenetic therapies. He serves on the editorial board of Blood, JCI, and on the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society. He has earned the Dameshek Prize from the American Society of Hematology, a Scholar Award from the Leukemia and Lymphoma Society, a Young Investigator Award from the American Society of Clinical Oncology, a Scholar Award from the American Society of Hematology, the Boyer Award for Clinical Investigation from MSKCC, a Clinical Scientist Development Award from the Doris Duke Charitable Foundation and a NCI Outstanding Investigator R35 award for his work on cancer epigenetics. In 2011 he was elected to the American Society of Clinical Investigation and in 2018 to the Association of American Physicians.

sab-Christopher-Kirk

Christopher Kirk, Ph.D.

Christopher Kirk, Ph.D., is co-founder, President and Chief Scientific Officer, of Kezar Life Sciences (NASDQ : KZR), a clinical-stage, San Francisco Bay Area-based biotechnology company focused on drug discovery and development in autoimmunity and oncology. Prior to Kezar, he was the Vice President of Research at Onyx Pharmaceuticals where he played a key leadership role in the discovery and development of 2 proteasome inhibitors, carfilzomib (KYPROLIS™), currently approved for the treatment of multiple myeloma, and oprozomib, currently in Phase 2 testing. Dr. Kirk has authored multiple publications in journals including Cell, Nature Medicine, and Nature Reviews and is listed as an inventor on over 25 patents. He sits on the scientific advisory board at Karyopharm Therapeutics, Inc., Avidity Biosciences LLC, Rain Therapeutics, Inc., and the Institute of Applied Clinical Science at the M.D. Anderson Cancer Center. Dr. Kirk received his B.S. degree in Biochemistry from University of California, Davis, and his Ph.D. degree in Cellular and Molecular Biology from the University of Michigan.

sab-Ryan-B-Corcoran

Ryan B. Corcoran, M.D., Ph.D.

Dr. Ryan Corcoran is the Director of the Gastrointestinal Cancer Center Program and the Scientific Director of the Termeer Center for Targeted Therapy at the Massachusetts General Hospital Cancer Center. He is an Associate Professor of Medicine at Harvard Medical School. Dr. Corcoran received his A.B. from Princeton University, and his M.D./Ph.D. from Stanford University. He completed his residency in Internal Medicine at the Massachusetts General Hospital and his fellowship in Medical Oncology at the Dana Faber Cancer Institute and the Massachusetts General Hospital Cancer Center. Dr. Corcoran directs a research laboratory focused on personalized cancer medicine: the development of therapeutic strategies that target the specific mutations driving individual patients’ tumors. His work focuses on understanding the molecular determinants of response or resistance to anti-cancer therapies. Dr. Corcoran’s laboratory is also studying new ways to utilize liquid biopsy, and specifically analysis of circulating tumor DNA, in the clinic to optimize how we deliver cancer care to individual patients. Dr. Corcoran is a member of the National Cancer Institute Colorectal Cancer Task Force and the Rectal Cancer Task Force, and an elected member of the American Society for Clinical Investigation (ASCI).

bod-Ken-Anderson

Ken Anderson, M.D.

Ken Anderson, M.D. is a co-founder and has served as a member of our Board since December 2015. Dr. Anderson has also served as the Kraft Family Professor of Medicine at Harvard Medical School since 2002, as well as Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute since 2000 and 2007, respectively. Dr. Anderson is a member of the Institute of Medicine of the National Academy of Sciences and served as President of the International Myeloma Society from 2011 until 2015. Dr. Anderson serves on the boards of directors of Mana Therapeutics, Inc., a biotechnology company developing off-the-shelf cellular therapies for cancer patients, since January 2018, OncoPep, Inc. a biotechnology company developing targeted immunotherapeutics, since January 2010, NextRNA, a biotechnology company focused on developing the next generation of RNA-directed therapeutics, since February 2021, Raqia Therapeutics, Inc., a CAR-T cell therapies company for cancer and other diseases, since September 2020, and Starton Therapeutics, Inc., a biotechnology company focused on blood cancer treatments, since September 2020. Dr. Anderson holds an M.D. from Johns Hopkins Medical School, where he also trained in internal medicine, and completed hematology, medical oncology and tumor immunology training at Dana-Farber Cancer Institute.